# A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

> **NCT00538785** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 1236 (actual)

## Conditions studied

- Congenital Heart Disease

## Interventions

- **BIOLOGICAL:** Motavizumab
- **BIOLOGICAL:** Palivizumab

## Key facts

- **NCT ID:** NCT00538785
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 1236 (ACTUAL)
- **Last updated:** 2012-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00538785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00538785, "A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00538785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*